Chiome Bioscience Inc. (TYO:4583)

Market Cap	5.38B -41.2%
Revenue (ttm)	593.29M -24.0%
Net Income	-982.78M
EPS	-14.47
Shares Out	72.64M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,065,500
Open	75.00
Previous Close	76.00
Day's Range	71.00 - 75.00
52-Week Range	72.00 - 168.00
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Chiome Bioscience

Chiome Bioscience Inc. engages in the research and development of antibody drugs in Japan, Singapore, and internationally. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib system, a monoclonal antibody production technology that uses chicken immune cells to produce antibodies for drug discovery research. It also develops drugs under Phase I clinical trial, including ADCT-701, a humanized anti-dlk1 antibody for the treatment of solid tumors; CBA-1205, a humanized afucosylated anti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 53
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4583

Financial Performance

In 2025, Chiome Bioscience's revenue was 593.29 million, a decrease of -24.02% compared to the previous year's 780.81 million. Losses were -982.78 million, -3.72% less than in 2024.